Jennifer Buell, President and Chief Executive Officer at MiNK Therapeutics, shared MiNK Therapeutics’s post on X, adding:
“Children with aggressive cancers face far too few options.
Today MiNK Therapeutics announced a collaboration with C-Further, supported by Cancer Research Horizons and LifeArc, to advance a PRAME-targeted iNKT cell therapy for pediatric cancers.
PRAME is shared across several difficult-to-treat tumors. Our goal: apply the precision of engineered immune cells to children who urgently need better options – while continuing to drive the next generation of cell therapy innovation in the U.S.”
Quoting MiNK Therapeutics‘ post:
“MiNK Therapeutics has announced a collaboration with C-Further and the University of Southampton to advance a PRAME-targeted TCR-engineered iNKT cell therapy for pediatric cancers.
The program combines PRAME targeting with MiNK’s off-the-shelf iNKT platform, aiming to accelerate development of new immune therapies for children facing cancers with limited options.”
Other articles featuring Jennifer Buell on OncoDaily.